Company registration number 14027798 (England and Wales)
CELL SUPPLY LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 APRIL 2023
PAGES FOR FILING WITH REGISTRAR
CELL SUPPLY LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
CELL SUPPLY LTD
BALANCE SHEET
AS AT 30 APRIL 2023
30 April 2023
- 1 -
2023
Notes
£
£
Fixed assets
Tangible assets
4
34,204
Current assets
Stocks
8,500
Debtors
5
320
Cash at bank and in hand
79,457
88,277
Creditors: amounts falling due within one year
6
(187,800)
Net current liabilities
(99,523)
Net liabilities
(65,319)
Capital and reserves
Called up share capital
7
1
Profit and loss reserves
(65,320)
Total equity
(65,319)
CELL SUPPLY LTD
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2023
30 April 2023
- 2 -

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial Period ended 30 April 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The member has not required the company to obtain an audit of its financial statements for the Period in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 5 April 2024
Mr O  Osborne
Director
Company Registration No. 14027798
CELL SUPPLY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 APRIL 2023
- 3 -
1
Accounting policies
Company information

Cell Supply Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 21 Granary Court, South Warnborough, Hook, Hampshire, England, RG29 1RP.

1.1
Reporting period

The financial statements cover the period from incorporation, 05 April 2022 to 30 April 2023.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

 

Sale of goods are recognised when goods are shipped and title has passed.

 

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
20% reducing balance
Fixtures and fittings
20% reducing balance
Computers
3 years straight line
Motor vehicles
20% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets. A provision is made for any impairment loss and taken to the profit and loss account.

CELL SUPPLY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 4 -

 

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company only enters into Basic financial instrument transactions.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

CELL SUPPLY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 5 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the Period was:

2023
Number
Total
3
CELL SUPPLY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 APRIL 2023
- 6 -
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 5 April 2022
-
0
-
0
-
0
Additions
14,644
30,692
45,336
At 30 April 2023
14,644
30,692
45,336
Depreciation and impairment
At 5 April 2022
-
0
-
0
-
0
Depreciation charged in the Period
2,929
8,203
11,132
At 30 April 2023
2,929
8,203
11,132
Carrying amount
At 30 April 2023
11,715
22,489
34,204
5
Debtors
2023
Amounts falling due within one year:
£
Trade debtors
320
6
Creditors: amounts falling due within one year
2023
£
Trade creditors
68,342
Taxation and social security
33,070
Other creditors
86,388
187,800
7
Called up share capital
2023
2023
Ordinary share capital
Number
£
Issued and fully paid
Ordinary of £1 each
1
1

One £1 ordinary share was issued on incorporation.

2023-04-302022-04-05false05 April 2024CCH SoftwareCCH Accounts Production 2023.300No description of principal activityMr O Osbornefalse140277982022-04-052023-04-30140277982023-04-3014027798core:LandBuildings2023-04-3014027798core:OtherPropertyPlantEquipment2023-04-3014027798core:CurrentFinancialInstrumentscore:WithinOneYear2023-04-3014027798core:CurrentFinancialInstruments2023-04-3014027798core:ShareCapital2023-04-3014027798core:RetainedEarningsAccumulatedLosses2023-04-3014027798bus:Director12022-04-052023-04-3014027798core:LeaseholdImprovements2022-04-052023-04-3014027798core:FurnitureFittings2022-04-052023-04-3014027798core:ComputerEquipment2022-04-052023-04-3014027798core:MotorVehicles2022-04-052023-04-3014027798core:LandBuildings2022-04-0414027798core:OtherPropertyPlantEquipment2022-04-04140277982022-04-0414027798core:LandBuildings2022-04-052023-04-3014027798core:OtherPropertyPlantEquipment2022-04-052023-04-3014027798bus:PrivateLimitedCompanyLtd2022-04-052023-04-3014027798bus:SmallCompaniesRegimeForAccounts2022-04-052023-04-3014027798bus:FRS1022022-04-052023-04-3014027798bus:AuditExemptWithAccountantsReport2022-04-052023-04-3014027798bus:FullAccounts2022-04-052023-04-30xbrli:purexbrli:sharesiso4217:GBP